Belshe, R.Newman, F.Anderson, E.Wright, P.Karron, R.Tollefson, S.Henderson, F.Meissner, H.Madhi, S.Roberton, D.Marshall, H.Loh, R.Sly, P.Murphy, B.Tatem, J.Randolph, V.Hackell, J.Gruber, W.Tsai, T.2006-06-232006-06-232004Journal of Infectious Diseases, 2004; 190(12):2096-21030022-18991537-6613http://hdl.handle.net/2440/7511© 2004 by the Infectious Diseases Society of America. All rights reserved.We evaluated a combination respiratory syncytial virus (RSV) and parainfluenza 3 virus (PIV3) live, attenuated intranasal vaccine for safety, viral replication, and immunogenicity in doubly seronegative children 6–18 months old. RSV cpts-248/404 and PIV3-cp45 vaccines were combined in a dose of 105 plaque-forming units of each per 0.5-mL dose and compared with monovalent vaccines or placebo. The virus shedding pattern of RSV was not different between monovalent RSV cpts-248/404 vaccine and combination vaccine. Modest reductions in the shedding of PIV3-cp45 vaccine virus were found after the administration of RSV cpts-248/404 and PIV3-cp45 vaccine, relative to monovalent PIV3 vaccine; 16 (76%) of 21 children given combination vaccine shed PIV3-cp45 versus 11 (92%) of 12 of those given monovalent PIV3 vaccine. Both vaccines were immunogenic, and antibody responses were similar between the monovalent groups and the combination group. Combined RSV/PV3 vaccine is feasible for simultaneous administration, and further studies are warranted.enHumansParainfluenza Virus 3, HumanRespirovirus InfectionsRespiratory Syncytial Virus InfectionsVaccines, CombinedParainfluenza VaccinesRespiratory Syncytial Virus VaccinesAntibodies, ViralAdministration, IntranasalDouble-Blind MethodVirus SheddingInfantJournal article002004152610.1086/4259810002252816000062-s2.0-1044425561056241Marshall, H. [0000-0003-2521-5166]